Clinical Trials in Baltimore

Showing 7361-7380 of 17,842 trials

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911

This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.

Cardiovascular DiseasesHepatitis CHiv

University of Maryland, Baltimore87 participantsStarted Nov 2018

Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States

COMPLETEDPhase 2< 1 mile

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

NCT00602459

This randomized phase II trial studies how well fludarabine (fludarabine phosphate) and rituximab with or without lenalidomide or cyclophosphamide work in treating patients with symptomatic chronic lymphocytic leukemia. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Giving fludarabine phosphate and rituximab together with lenalidomide or cyclophosphamide may be an effective treatment for chronic lymphocytic leukemia.

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more

National Cancer Institute (NCI)418 participantsStarted Jan 2008

Scottsdale, Arizona, United States • Arroyo Grande, California, United States • Burbank, California, United States +361 more locations

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Find Trials by Condition in Baltimore

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

HBV-HIV Coinfection Research Network

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Acupuncture in Spinal Cord Injury Subjects

A 6 Month Safety Extension Study of MBGS205

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Protect the Head to Head Study

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

Multisystemic Therapy-Emerging Adults Trial

Glycemic Control and the Brain in Children With Type 1 Diabetes

A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma

Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma